HYDERABAD | 11 August 2026: US-based biotechnology company Amgen has announced plans to establish a new Science & Innovation Center in Genome Valley, Hyderabad, expanding its global research and development footprint in India. Expected to become operational in 2027, the new facility will form part of Amgen’s global R&D network of seven research laboratories and will bring together experimental science, data and technology capabilities. The centre will complement Amgen’s existing technology and innovation presence in Hyderabad, strengthening the integration of scientific and digital capabilities within the company’s global R&D model.

KEY HIGHLIGHTS

  • The 2027 R&D Expansion: The Hyderabad facility is expected to become operational in 2027 and will join Amgen’s global network of seven research laboratories.
  • Science + Technology Convergence: The centre is designed to bring together experimental science, data and technology, creating closer integration between laboratory-based research and digital capabilities.
  • Next-Generation R&D Capabilities: The facility will bring together scientists and technologists working across discovery chemistry, drug metabolism and pharmacokinetics (DMPK), and precision medicine.
  • Hyderabad’s Expanding Role: The Science & Innovation Center will complement Amgen’s existing technology and innovation site in Hyderabad, creating a broader scientific and technology ecosystem within the city.
  • Government Partnership: The investment is being formalised through an MoU with the Government of Telangana, further strengthening Hyderabad’s positioning as a location for high-value life sciences and research capabilities.

Amgen is a biotechnology company that discovers, develops, manufactures and delivers medicines across areas including oncology, cardiovascular disease, inflammation, rare diseases and general medicine. Amgen has nearly 27,000 employees and a presence in approximately 100 countries and regions.

As the biopharmaceutical industry becomes increasingly data-intensive, the boundaries between traditional laboratory science and computational science are also becoming less distinct. Amgen itself describes its research model as increasingly combining AI, generative biology and human data with advanced scientific capabilities. By establishing a new scientific facility in Genome Valley alongside its existing technology presence, Amgen is building greater proximity between experimental science and digital capability in Hyderabad.

THE INNOVATION MANDATE: ENGINEERING THE FUTURE OF DRUG DISCOVERY

“

The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities and complements our strong US-based Research and Development footprint. By connecting these capabilities, we can learn faster and translate those insights into innovative medicines for patients.

– Dr Jay Bradner, EVP, Research & Development, AI & Data, Amgen

The capability mix reveals a targeted expansion across core areas of therapeutic discovery:

  • Advanced Discovery Chemistry: The Genome Valley centre will support discovery chemistry, enabling scientists to design, evaluate and refine potential therapeutic compounds as part of Amgen’s broader R&D network.
  • Drug Metabolism & Pharmacokinetics: DMPK capabilities will form part of the centre’s scientific mandate, supporting the evaluation of how potential therapies behave within the body and informing decisions during drug discovery and development.
  • Precision Medicine: The centre will also contribute to precision medicine capabilities, bringing together scientific, data and technology expertise to support more targeted approaches to drug development.
“

Genome Valley offers strong scientific expertise and infrastructure, and the new facility will complement Amgen’s existing technology and innovation site in Hyderabad. Together, the sites will enable closer integration of wet-laboratory science with innovative technology, advancing how we develop medicines.

– Naveen Gullapalli, Managing Director, Amgen India

TECHNOLOGY CONTEXT: CONNECTING EXPERIMENTAL SCIENCE WITH DIGITAL INNOVATION

The establishment of the Science & Innovation Center represents the scientific counterpart to Amgen’s existing technology and innovation presence in Hyderabad. The strategic opportunity is not simply to colocate scientific and technology teams, but to create stronger connections between experimental data, computational analysis, AI and scientific decision-making.

Amgen’s broader research model already demonstrates this direction. Its next-generation laboratories bring chemistry, biology, protein science, assay expertise, automation and data science together, with a focus on accelerating the continuous Design-Make-Test-Analyze (DMTA) cycle.

The same convergence is visible in Amgen’s expanding Hyderabad talent base. Current research hiring includes capabilities in NGS bioinformatics, algorithm development, biomarker analysis, precision medicine, biostatistics and data science, illustrating the increasingly multidisciplinary nature of its India R&D ecosystem.

Industry Insights

  1. India Is Moving Deeper into Life Sciences R&D: Amgen’s investment places India closer to the core scientific value chain, beyond technology and support services.
  2. Wet Lab + Data + AI Is the Emerging R&D Model: The convergence of experimental science, data and technology is becoming central to faster, more informed drug discovery.
  3. Domain + Digital Talent Is the New Capability Equation: The combination of scientists, computational specialists, data scientists and AI talent is creating a more integrated life sciences capability model in India.
  4. Hyderabad’s Advantage Is Ecosystem Depth: Amgen’s choice of Genome Valley alongside its existing technology presence demonstrates the value of combining scientific infrastructure, specialised talent and digital capabilities within one ecosystem.

AMGEN’S DESIGN-MAKE-TEST-ANALYZE MODEL

Amgen’s next-generation laboratory model provides a useful illustration of where biopharma R&D is heading. The Design-Make-Test-Analyze (DMTA) cycle brings chemistry, biology, protein science, assay expertise, automation and data science into a more integrated workflow. Scientists can use shared data and insights to design the next experiment or molecule faster, improving both the speed and quality of learning throughout discovery.

This is directly relevant to the Hyderabad opportunity. The strategic value of the new centre is not simply the presence of wet-lab infrastructure. It is the opportunity to connect scientific experimentation with computation, data and technology so that research teams can learn faster and make better decisions.

GCC implication: The next generation of life sciences capability centres will increasingly need to integrate scientific expertise, computational science, data engineering and AI rather than treating digital and R&D capabilities as separate domains.

INDUSTRY PERSPECTIVE: THE LIFE SCIENCES GCC IS EVOLVING

Amgen’s expansion reflects a broader evolution in the role of India-based life sciences capability.

The earlier model centred largely on areas such as IT, finance, clinical operations and shared services. The emerging model increasingly extends into drug discovery, bioinformatics, precision medicine, scientific analytics and AI-enabled R&D.

This changes the strategic value proposition of the GCC as the headquarters focus has shifted to “parts of the global scientific value chain that India can build.” Amgen’s Hyderabad expansion is an instance of that transition.

WAY FORWARD

While the establishment of the Amgen Science & Innovation Center in Genome Valley represents another life sciences investment in Hyderabad, it also implies to the key role that India can now play within global biopharma R&D. The strategic significance lies in the combination of capabilities: experimental science in Genome Valley, technology and innovation capabilities already established in Hyderabad, and access to a growing pool of specialised scientific, computational and data talent.

As drug discovery becomes increasingly dependent on the interaction between biology, data, automation and AI, the competitive advantage will increasingly come from how quickly these disciplines can learn from one another. Amgen’s Hyderabad expansion therefore points towards a more advanced GCC model, one in which India contributes not only technology and operational capability, but scientific capacity, research intelligence and innovation to the global development of medicines.

Curated by SSF Global

Tracking the shifts shaping GCCs, enterprise ecosystems, and the future of global business.

Share on      

SSF Global is a Global Community for Enterprise Function Leaders and serves as a research & advisory platform focused on Global Business Services (GBS), Global Capability Centres (GCCs), and the evolution of enterprise innovation in India and beyond. We track, publish, and partner in narratives that shape how capability centres transform into hubs of trust, intelligence, and sustainable growth. We also evaluate, assess and benchmark the GCCs for their performance, maturity and other parameters using our proprietary tools built from the knowledge gained from direct interaction with our members (GCCs & GBS).